trial

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.

NCTId NCT07371325
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 36 (actual)
Sponsored by Manuel Jesús Cuesta Zurita
Primary completion 2026-01-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2024-09-08
Primary completion
2026-01-23
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participantsAtypical antipsychotics (AAP)

Sponsors

Manuel Jesús Cuesta ZuritaLead Sponsor
GENBIOMA Aplicaciones SLCollaborator
Universidad Pública de NavarraCollaborator

Sites

1 total
Pamplona, Spain

Facts & assertions

4 sourced
Enrollment
36
Phase
NA
Primary Completion Date
2026-01-23
Status
COMPLETED
relationships
The graph out of here
drug
Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants
drug
Atypical antipsychotics (AAP)
drug
lead_sponsor
Manuel Jesús Cuesta Zurita
company
collaborator
GENBIOMA Aplicaciones SL
company
Universidad Pública de Navarra
company
indication
Metabolic Abnormalities
indication
Metabolic Syndrome
indication
Postbiotic Supplement
indication